NCT03737994 2026-03-18Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerNational Cancer Institute (NCI)Phase 2 Active not recruiting10 enrolled 17 charts
NCT03726333 2024-06-21Hepatic Impairment Study for Lorlatinib in Cancer PatientsPfizerPhase 1 Terminated1 enrolled 3 charts